You searched for "invasive"

391 results found

Shared decision-making – minimising the mismatch

In Western countries, we are spoilt for choice in almost every aspect of our lives, but does that reflect also in healthcare? While we have taken some big strides towards shared decision-making with our patients, the age-old physician dominance remains...

Action Bladder Cancer UK awards grants for bladder cancer research

Action Bladder Cancer UK has granted funding to enable vital research into bladder cancer as part of its annual ABC UK Improving Outcomes for Patients Programme (https://actionbladdercanceruk.org/abc-uk-grants/). The five grant recipients will undertake significant studies, ranging from the analysis of...

Transurethral en bloc resection versus standard resection of bladder tumour

Bladder cancer is a common urological malignancy, with around 610,000 new cases and 220,000 deaths worldwide in 2022. Approximately 75% of these cases are non-muscle-invasive bladder cancer (NMIBC). The conventional method for treating NMIBC is standard resection (SR), performed transurethrally,...

Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer

Biomarkers play an essential role in the diagnosis and treatment of urothelial cancer (UC), with PD-L1, FGFR, and MMR proteins being the most clinically established. These biomarkers, derived from histological specimens, guide therapeutic decisions for bladder cancer (BCa) and upper...

The Urology Foundation – 2019 Report

It has been another busy year for The Urology Foundation in our mission to end the suffering caused by urology disease. We’ve taken big strides in some of the most crucial areas of our work as we work to prevent, treat and cure all urology disease.

Delivering a laparoscopic urology workshop in West Africa: our initial experience in Senegal

Despite universal adoption and significant technological innovation since its inception around 30 years ago, access to laparoscopic surgery remains lacking in Sub-Saharan Africa (SSA). Whilst some progress has been made in recent years to bridge the gap with the developed...

All you need to know about percutaneous nephrolithotomy: supine versus prone and mini versus traditional

Introduction Since the first percutaneous nephrolithotomy (PCNL), the technique has undergone many innovations, including modifications in positioning, miniaturisation of instruments and combination with retrograde intra-renal surgery (see Table 1 for an outline of the history of the technique). Controversy has...

Post radical nephrectomy presenting with skull metastasis

We present the case of an 83-year-old female who underwent right radical nephrectomy for renal cell carcinoma (RCC). Despite negative surgical margins, the patient presented with a skull metastasis six years post radical nephrectomy. This case highlights the importance of...

Prostate abscess

Prostate abscess (PA) is a relatively uncommon clinical condition which is often difficult to diagnose because clinical symptoms are non-specific. It may be associated with a significant fatality rate, estimated to be between 3% and 30%, which may reflect its...

Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update

The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...

Inguino-scrotal sarcomas

A sarcoma is a malignant tumour that originates from mesenchymal cells such as adipose tissue, bone, cartilage and smooth muscle. Although these tumours histologically do not originate from the urogenital tract, urologists are often involved in their diagnosis and management...

One cycle of adjuvant chemotherapy in tumours of the testis

Following a radical orchiectomy, current UK practice for newly diagnosed, high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis (NSCGCTT) is either two cycles of adjuvant chemotherapy with bleomycin, etoposide, cisplatin (BE360Px2) or surveillance with BE500Px3 on...